Canqura originated as a project headed by Professor Bror Morein, now Professor emeritus of virology linked to Clinical Virology Department at Uppsala University looking into the possibilities of treating cancer by research into Nanoparticulate Quillaja saponin. This treatment induces apoptosis, particularly in human leukemia cell lines with a high therapeutic index. Prof Morein has more than 200 publications, 20 patents and patent applications in vaccinology. Canqura is now actively engaged under current management with taking this technology forward. A supply Agreement with CRODA INTERNATIONAL PLC has been signed to supply C-100 for the purposes of our research and arrangements are in process for conclusive live tests into 2020.
THE MANAGEMENT TEAM
|Johan Monie||Managing Director, Board Memberfirstname.lastname@example.org|
|Lars Monie||Board Memberemail@example.com|
|Jeremy Clark||Board Memberfirstname.lastname@example.org|